ECSP045214A - Proceso para la elaboración de inhibidores de reductasa hmg-coa - Google Patents

Proceso para la elaboración de inhibidores de reductasa hmg-coa

Info

Publication number
ECSP045214A
ECSP045214A EC2004005214A ECSP045214A ECSP045214A EC SP045214 A ECSP045214 A EC SP045214A EC 2004005214 A EC2004005214 A EC 2004005214A EC SP045214 A ECSP045214 A EC SP045214A EC SP045214 A ECSP045214 A EC SP045214A
Authority
EC
Ecuador
Prior art keywords
hmg
elaboration
coa reductase
reductase inhibitors
sub
Prior art date
Application number
EC2004005214A
Other languages
English (en)
Inventor
Murat Acemoglu
Bernhard Riss
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of ECSP045214A publication Critical patent/ECSP045214A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D215/14—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Abstract

La invención se refiere a un proceso para la elaboración de un compuesto de la fórmula (I) o una sal, especialmente una sal farmacéuticamente aceptable con una base, del mismo o una lactona del mismo en donde el elemento (II) representa -CH2-CH2- o -CH=CH- y R representa un residuo cíclico.
EC2004005214A 2002-01-31 2004-07-30 Proceso para la elaboración de inhibidores de reductasa hmg-coa ECSP045214A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US35378702P 2002-01-31 2002-01-31

Publications (1)

Publication Number Publication Date
ECSP045214A true ECSP045214A (es) 2004-09-28

Family

ID=27663254

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2004005214A ECSP045214A (es) 2002-01-31 2004-07-30 Proceso para la elaboración de inhibidores de reductasa hmg-coa

Country Status (23)

Country Link
US (2) US7371865B2 (es)
EP (1) EP1472228B1 (es)
JP (1) JP4524111B2 (es)
KR (1) KR20040081161A (es)
CN (1) CN1305853C (es)
AT (1) ATE426594T1 (es)
AU (1) AU2003226971B2 (es)
BR (1) BR0307303A (es)
CA (1) CA2472776C (es)
CO (1) CO5601005A2 (es)
DE (1) DE60326819D1 (es)
EC (1) ECSP045214A (es)
ES (1) ES2323267T3 (es)
HK (1) HK1070651A1 (es)
IL (1) IL162980A (es)
MX (1) MXPA04007396A (es)
NO (1) NO327091B1 (es)
NZ (1) NZ534232A (es)
PL (1) PL370658A1 (es)
PT (1) PT1472228E (es)
RU (1) RU2299196C2 (es)
WO (1) WO2003064392A1 (es)
ZA (1) ZA200405322B (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5192147B2 (ja) * 2003-02-12 2013-05-08 日産化学工業株式会社 ピタバスタチンカルシウムの結晶質形態
JPWO2004094385A1 (ja) * 2003-04-24 2006-07-13 ダイセル化学工業株式会社 （３ｒ，５ｓ，６ｅ）−７−［２−シクロプロピル−４−（４−フルオロフェニル）キノリン−３−イル］−３，５−ジヒドロキシ−６−ヘプテン酸エチルの製造方法
TWI328006B (en) * 2003-12-26 2010-08-01 Nissan Chemical Ind Ltd Crystal form of quinoline compound and process for its production
EP1817027A2 (en) * 2004-09-27 2007-08-15 Ranbaxy Laboratories Limited Process for preparating enantiomerically pure fluvastatin sodium and a novel polymorphic form thereof
SI2024341T1 (sl) * 2006-05-03 2016-04-29 Msn Laboratories Private Limited Novi postopek za statine in njihove farmacevtsko sprejemljive soli
ES2567171T3 (es) * 2006-10-09 2016-04-20 Msn Laboratories Private Limited Nuevo procedimiento para la preparación de estatinas y sus sales farmacéuticamente aceptables
EP2032587A2 (en) 2007-04-18 2009-03-11 Teva Pharmaceutical Industries Ltd. Rosuvastatin intermediates and process for the preparation of rosuvastatin
JP2010533188A (ja) * 2007-07-12 2010-10-21 テバ ファーマシューティカル インダストリーズ リミティド ロバスタチン中間体及びその製法
US8487105B2 (en) * 2009-01-19 2013-07-16 Msn Laboratories Limited Process for preparing pitavastatin, intermediates and pharmaceuctically acceptable salts thereof
KR101160152B1 (ko) * 2009-02-24 2012-06-27 한미사이언스 주식회사 스타틴 화합물 또는 그 염의 신규 제조방법, 및 이에 사용되는 중간체 화합물
WO2011086584A2 (en) 2010-01-18 2011-07-21 Msn Laboratories Limited Improved process for the preparation of amide intermediates and their use thereof
US8759518B2 (en) * 2010-02-23 2014-06-24 Cadila Healthcare Limited Intermediates for the preparation of HMG CoA reductase inhibitors and processes for the preparation thereof
EP2383260A3 (en) 2010-04-30 2011-12-28 Dipharma Francis S.r.l. Process for the preparation of statins
WO2011141934A1 (en) 2010-05-13 2011-11-17 Matrix Laboratories Ltd. An improved process for the preparation of an intermediate of hmg-coa reductase inhibitors
CN103025727B (zh) * 2010-07-01 2015-09-02 柳韩洋行 HMG-CoA还原酶抑制剂及其中间体的制备方法
WO2012063254A1 (en) * 2010-11-12 2012-05-18 Hetero Research Foundation Novel polymorphs of pitavastatin calcium
WO2013080219A2 (en) 2011-11-28 2013-06-06 Mylan Laboratories Ltd NOVEL PROCESS FOR THE PREPARATION OF INTERMEDIATES OF HMG-CoA REDUCTASE INHIBITORS
CN103288871A (zh) * 2012-02-28 2013-09-11 浙江京新药业股份有限公司 一种制备二羟基酸HMG-CoA还原酶抑制剂用的中间体及其制备方法和应用
ITVI20130039A1 (it) 2013-02-20 2014-08-21 F I S Fabbrica Italiana Sint I S P A Processo per la preparazione di intermedi chiave per la sintesi di statine
CN103172656B (zh) * 2013-04-02 2015-07-08 浙江科技学院 3-二甲基叔丁基硅氧基戊二酸酐的合成工艺
CN111518035A (zh) * 2020-06-18 2020-08-11 安徽鼎旺医药有限公司 一种瑞舒伐他汀叔丁胺盐及其制备方法
CN113683539B (zh) * 2021-09-23 2023-05-16 上海裕兰生物科技有限公司 一种聚酮中间体的合成方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5354772A (en) * 1982-11-22 1994-10-11 Sandoz Pharm. Corp. Indole analogs of mevalonolactone and derivatives thereof
US4650890A (en) * 1984-04-03 1987-03-17 Sandoz Corp. Preparation of olefinic compounds and intermediates thereof
CA1336714C (en) 1987-08-20 1995-08-15 Yoshihiro Fujikawa Quinoline type mevalonolactone inhibitors of cholesterol biosynthesis
JP2569746B2 (ja) * 1987-08-20 1997-01-08 日産化学工業株式会社 キノリン系メバロノラクトン類
US4804770A (en) 1988-04-29 1989-02-14 E. R. Squibb & Sons, Inc. Process for preparing a keto-phosphonate intermediate useful in preparing HMG-CoA reductase inhibitors
DE3911064A1 (de) * 1989-04-06 1990-10-11 Bayer Ag Substituierte 1,8-naphthyridine
US5049577A (en) * 1990-01-29 1991-09-17 E. R. Squibb & Sons, Inc. 2-pyrrolidone substituted dihydroxy alkanoic, alkenoic and alkynoic acids, compositions and HMG-CoA reductase inhibition therewith
JP3528186B2 (ja) 1991-06-24 2004-05-17 日産化学工業株式会社 光学活性キノリンメバロン酸のジアステレオマー塩
DK1341785T3 (da) * 2000-11-16 2009-01-26 Teva Pharma Hydrolyse af R (R*,R*)-2-(4-fluorphenyl)-beta.delta-dihydroxy-5 (1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-1H-pyrrol-1-heptansyrester med calciumhydroxid
AU2002228413B8 (en) * 2001-02-02 2007-03-22 Mitsubishi Chemical Corporation Process for producing (3R,5S)-(E)-7-[2-Cyclopropyl-4-(4-Fluorophenyl)-Quinolin-3-yl]-3,5-Dihydroxyhept -6-enic acid esters
JP4433156B2 (ja) * 2001-11-14 2010-03-17 日産化学工業株式会社 光学活性オキソヘプテン酸エステルの製造方法
US6835838B2 (en) * 2002-01-28 2004-12-28 Novartis Ag Process for the manufacture of organic compounds
GB0210234D0 (en) * 2002-05-03 2002-06-12 Novartis Ag Process for the manufacture of organic compounds

Also Published As

Publication number Publication date
US20080182873A1 (en) 2008-07-31
ES2323267T3 (es) 2009-07-10
EP1472228A1 (en) 2004-11-03
US20050070605A1 (en) 2005-03-31
KR20040081161A (ko) 2004-09-20
PL370658A1 (en) 2005-05-30
NO20043611L (no) 2004-08-30
CO5601005A2 (es) 2006-01-31
EP1472228B1 (en) 2009-03-25
DE60326819D1 (de) 2009-05-07
CN1305853C (zh) 2007-03-21
JP2005520814A (ja) 2005-07-14
CN1622937A (zh) 2005-06-01
ATE426594T1 (de) 2009-04-15
AU2003226971B2 (en) 2006-11-30
JP4524111B2 (ja) 2010-08-11
MXPA04007396A (es) 2004-10-11
RU2299196C2 (ru) 2007-05-20
CA2472776A1 (en) 2003-08-07
ZA200405322B (en) 2005-07-27
IL162980A (en) 2010-02-17
NZ534232A (en) 2006-03-31
WO2003064392A1 (en) 2003-08-07
RU2004126442A (ru) 2005-06-10
US7371865B2 (en) 2008-05-13
HK1070651A1 (en) 2005-06-24
PT1472228E (pt) 2009-06-24
BR0307303A (pt) 2005-01-11
NO327091B1 (no) 2009-04-20
CA2472776C (en) 2011-01-25

Similar Documents

Publication Publication Date Title
HK1070651A1 (en) Process for the manufacture of hmg-coa reductase inhibitors
ECSP055913A (es) Inhibidores de las polimerasas víricas
EA201200954A1 (ru) Способ получения полугидрата гидрохлорида (r)-8-хлор-1-метил-2,3,4,5-тетрагидро-1н-3-бензазепина, фармацевтическая композиция на его основе и его применение
EA200870117A1 (ru) Азаиндоловые ингибиторы аурора-киназ
MA27624A1 (fr) Procede pour realiser une preparation enrobee
EP2299508A3 (en) Organic photosensitive optoelectronic device having a phenanthroline exciton blocking layer
IL177537A (en) Viral polymerase inhibitors, and pharmacological compounds containing them
EP1549315A4 (en) DIHYDROXYPYRIDOPYRAZINE-1,6-DION COMPOUNDS AS HIV INTEGRASE INHIBITORS
WO2005046589A3 (en) Pharmaceutically acceptable salts of quinolinone compounds having improved pharmaceutical properties
UA93351C2 (uk) Похідні фталазіну як інгібітори parp
EA200701121A1 (ru) Потенциаторы рецепторов глутамата
EA200400491A1 (ru) Полиморфная форма римонабанта, способ её получения и содержащие её фармацевтические композиции
EP1975164A3 (en) Octahydrobenzimidazolone compounds as analgetics
EA200400467A1 (ru) Производные 3-азабицикло (3.1.0) гексана в качестве антагонистов опиоидного рецептора
HK1076816A1 (es)
AU2003250471A8 (en) Pyrimidine-2,4-dione derivatives as matrix metalloproteinase inhibitors
EA200401455A1 (ru) Производные бензоксазина в качестве модуляторов 5-htи их применение
EA200301120A1 (ru) Цитрат 5,8,14-триазатетрацикло (10.3.1.0.0)-гексадека-2 (11),3,5,7,9-пентаена
MY138826A (en) 2,7-substituted indoles
DE60330758D1 (de) Bestimmte pharmazeutisch wertvolle substituierte aminoalkyl-heterocyclen
WO2004111008A3 (en) Use of a compound of formula i for making a pharmaceutical composition
EP2266971A3 (en) Hiv protease inhibiting compounds
DE60225694D1 (de) Fexofenadine hydrochlorid polymorph
MY129094A (en) Condensed polycyclic compounds
NO20053208L (no) Metode for reduktiv dehalogenering.